SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...
Increased exposure to nitrogen dioxide (NO2) and particulate matter with a diameter of ≤ 2.5 µm (PM2.5) is associated with an increased risk for Parkinson's disease (PD) and dyskinesia, a new study ...
In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.
SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences (NBIX), Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive ...
This transcript has been edited for clarity. Martha Sajatovic, MD: Hello. I'm Dr Martha Sajatovic. I direct the Neurological and Behavioral Outcomes Center at University Hospitals Cleveland. Joining ...
Tardive dyskinesia (TD) can be addressed by the right intervention even in severe, refractory cases. These cases, characterized by involuntary muscle movements, are most often caused by antipsychotics ...
Despite being a mainstay of Parkinson's disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side-effects with long-term use. A recent human trial found that a new drug ...
A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of ...
Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback